You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

~ Buy the BYETTA (exenatide synthetic) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR BYETTA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Byetta

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00082381 ↗	Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin	Completed	Eli Lilly and Company	Phase 3	2003-06-01	This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082381 ↗	Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin	Completed	AstraZeneca	Phase 3	2003-06-01	This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 ↗	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	Eli Lilly and Company	Phase 3	2003-11-01	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
NCT00082407 ↗	Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin	Completed	AstraZeneca	Phase 3	2003-11-01	This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Byetta

Condition Name

Chart
Table

Condition Name for Byetta
Intervention	Trials
Type 2 Diabetes Mellitus	38
Type 2 Diabetes	18
Diabetes Mellitus, Type 2	13
Obesity	13
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Byetta
Intervention	Trials
Diabetes Mellitus	76
Diabetes Mellitus, Type 2	67
Obesity	9
Diabetes Mellitus, Type 1	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Byetta

Trials by Country

Map
Table

Trials by Country for Byetta
Location	Trials
United States	356
Canada	19
Mexico	15
Australia	14
United Kingdom	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Byetta
Location	Trials
Texas	31
California	22
Florida	16
Minnesota	14
Washington	14
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Byetta

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Byetta
Clinical Trial Phase	Trials
Phase 4	35
Phase 3	29
Phase 2/Phase 3	6
[disabled in preview]	20
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Byetta
Clinical Trial Phase	Trials
Completed	104
Unknown status	7
Terminated	5
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Byetta

Sponsor Name

Chart
Table

Sponsor Name for Byetta
Sponsor	Trials
Eli Lilly and Company	47
AstraZeneca	42
Amylin Pharmaceuticals, LLC.	16
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Byetta
Sponsor	Trials
Industry	124
Other	114
NIH	12
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.